Atnahs Pharma UK Ltd

11/17/2026 | Press release | Distributed by Public on 11/17/2026 02:54

Sepalna (senaparib) receives European Commission approval for first-line maintenance treatment in advanced ovarian cancer

This press release is intended exclusively for business, pharmaceutical and trade media. It is not intended for patient-facing communications or direct distribution to the general public.

BASILDON, UK, Tuesday 17th November 2026

Pharmanovia, the global specialty pharmaceutical company and IMPACT Therapeutics confirmed today that the European Commission (EC) has granted marketing authorisation for Sepalna® (senaparib) as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Pharmanovia is the exclusive regional development and commercialisation partner for senaparib, across 66 countries, including EU, United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and countries in MENA.

The EC decision was granted on 12 November 2026, following the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) in September 20262 and represents an important regulatory milestone for senaparib in Europe.

Developed by IMPACT Therapeutics, senaparib is a targeted anti-cancer therapy. The EC decision is based on the evidence package submitted in support of the marketing-authorisation application, including data from the Phase 3 FLAMES study. FLAMES (NCT04169997) is a randomised, double-blind, placebo-controlled Phase 3 study in patients with newly diagnosed advanced ovarian cancer responding to first-line platinum-based chemotherapy, irrespective of BRCA mutation status. Patients were randomised 2:1 to senaparib or placebo.

With a median follow-up of 48.5 months, data presented at ESMO 20261 revealed:

  • Median PFS assessed by blinded independent central review was 38.7 months (95% CI 28.0-not estimable) with senaparib versus 13.6 months (95% CI 10.9-16.6) with placebo (HR 0.47; 95% CI 0.36-0.62; p<0.0001).
  • A PFS benefit was observed in both the BRCA-mutated (median PFS 49.8 months; HR 0.41) and BRCA wild-type (median PFS 33.3 months; HR 0.49) subgroups.
  • In the updated safety analysis (n=403), 15 of 270 patients (5.6%) receiving senaparib discontinued treatment due to treatment-emergent adverse events. The most common treatment-emergent adverse events (≥20%) in the senaparib arm were anaemia, neutropenia, leukopenia, thrombocytopenia, transaminases increased, weight increased, nausea, abdominal pain. No treatment-emergent adverse events led to death.

Stephan Eder, Chief Executive Officer of Pharmanovia, commented, "The European Commission's approval of Sepalna represents an important milestone for patients with advanced ovarian cancer and for our growing oncology portfolio. We congratulate our partner IMPACT Therapeutics on this significant achievement, reflecting years of dedicated research and clinical development. Our focus at Pharmanovia is now on preparing for the introduction of Sepalna across Europe and working towards making this treatment available to eligible patients."

-Ends-

References:

1 Wu X, et al. Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC). Abstract 1260P. ESMO Congress 2026; Madrid, Spain; 26 October 2026

Full FLAMES data presented via e-poster at ESMO Congress 2026 in Madrid ESMO- https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/presentation/list?q=FLAMES

2 European Medicines Agency. Sepalna: CHMP summary of positive opinion. 18 September 2026. Accessed 16 November 2026.

Contact Pharmanovia

For additional information, please visit www.pharmanovia.com

Press office: 07442 256310

Email [email protected]

Contact IMPACT Therapeutics

For additional information, please visit www.impacttherapeutics.com

IMPACT Therapeutics Contact: +86 21 6841 1121

Investor Relations: [email protected]

Public Relations: [email protected]

About Pharmanovia

Pharmanovia is a global specialty pharmaceutical company. We partner with innovative biotech and large pharma to bring innovative specialty medicines to patients, while supporting trusted established brands across more than 160 markets.

About IMPACT Therapeutics (07630.HK)

Founded in 2009, IMPACT Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

Atnahs Pharma UK Ltd published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 08:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]